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Many active components of herbal products are small organic anions, and organic anion transporters were previously
demonstrated to be a potential site of drug-drug interactions. In this study, we assessed the inhibitory eﬀects of six hydrophilic
components of the herbal medicine Danshen, lithospermic acid, protocatechuic acid, rosmarinic acid, salvianolic acid A,
salvianolic acid B, and tanshinol, on the function of the murine organic anion transporters, mOat1 and mOat3. All of Danshen
components significantly inhibited mOat1- and mOat3-mediated substrate uptake (P < 0.001) with lithospermic acid (LSA),
protocatechuic acid, rosmarinic acid (RMA), and salvianolic acid A (SAA) producing virtually complete inhibition under test
conditions. Kinetic analysis demonstrated that LSA, RMA, and SAA were competitive inhibitors. As such, Ki values were estimated
as 14.9 ± 4.9μM for LSA, 5.5 ± 2.2μM for RMA, and 4.9 ± 2.2μM for SAA on mOat1-mediated transport, and as 31.1 ± 7.0μM
for LSA, 4.3 ± 0.2μM for RMA, and 21.3 ± 7.7μM for SAA on mOat3-mediated transport. These data suggest that herb-drug
interactions may occur in vivo on the human orthologs of these transporters in situations of polypharmacy involving Danshen
and clinical therapeutics known to be organic anion transporter substrates.
1. Introduction
The Chinese herbal medicine, Danshen (Salvia miltiorrhiza),
has been employed for thousands of years in the relief of
symptoms of cardiovascular disease [1–3]. Despite this long
history of medicinal use, the issue of which component(s)
is (are) responsible for its therapeutic eﬀects, and the
precise biochemical mechanisms underlying their absorp-
tion, distribution, and elimination, remain largely unknown.
Increasingly, six hydrophilic compounds, lithospermic acid
(LSA), protocatechuic acid (PCA) (in this work we use the
abbreviation PCA to designate protocatechuic acid. Some
previous reports have used PCA to refer to protocatechuic
aldehyde. Protocatechuic aldehyde is a major component
in Danshen extracts whereas the protocatechuic acid level
is insignificant), rosmarinic acid (RMA), salvianolic acid A
(SAA), salvianolic acid B (SAB), and tanshinol (TSL), are
gaining favor as the Danshen components responsible for
the beneficial eﬀects on heart disease [4–6]. Since these
compounds are organic, small in size (154–718Da), and exist
as anions at physiological pH, it is possible that they are
substrates and/or inhibitors of the organic anion transport
pathway that exists in organs such as the kidney, liver,
intestine, and choroid plexus [7].
We now know that this organic anion transport pathway
is actually a complex system of transport proteins that belong
to a variety of gene families. Members of the solute carrier
(SLC) superfamily, composed of ∼55 gene families contain-
ing almost 400 identified transporters, are an important
component of this pathway [7–9]. Of particular interest for
the Danshen components examined in this work is the SLC22
(organic cation/anion/zwitterion transporters) family, which
includes both the organic cation transporters and the organic
anion transporters (OATs). Members of the OAT family
are found in virtually every barrier tissue in the body and
mediate the transepithelial flux (absorption, distribution,
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and elimination) of a multitude of endogenous and xenobi-
otic compounds [7–9]. Typical endogenous OAT substrates
include sulfated steroid conjugates, indoxyl sulfate, uric acid,
and acidic metabolites of monoamine neurotransmitters.
Xenobiotic substrates include clinically important therapeu-
tics such as antibiotic (benzylpenicillin), antiviral (adefovir,
cidofovir) and anticancer (methotrexate) agents, statins,
and angiotensin-converting enzyme inhibitors, as well as
environmental toxins such as ochratoxin A and aristolochic
acid [7, 9, 10].
Currently, there are 29 putative SLC22 family members,
18 of which are believed to be OATs. Of those, transport
activity has been demonstrated for eleven, OAT1-10 and
URAT1 [7, 9]. OATs expressed in the proximal tubule cells
of the kidney mediate the blood to urine secretory flux and
urine to blood reabsorptive flux of substrate compounds
[7–9]. Since these compounds are negatively charged, OATs
provide a passageway through which they can readily cross
the lipid bilayer of cells. Substrate entry into proximal
tubule cells from the blood across the basolateral membrane
is energized by exchange for intracellular α-ketoglutarate
(i.e., organic anion/dicarboxylate exchange). In humans and
rodents this process involves the basolateral exchangers and
organic anion transporter 1 (Oat1; Slc22a6) and 3 (Oat3;
Slc22a8) [11, 12]. OAT-mediated exit of organic anions from
the cell into the urine is accomplished via facilitated diﬀusion
using the electrochemical gradient. There appears to be
distinct species diﬀerences between rodents and humans in
terms of OATs targeted to the apical membrane of proximal
tubule cells. For example, while both species express Urat1
(Slc22a12), humans also have OAT4 (SLC22A9; no current
rodent ortholog), whereas rodents have Oat5 (Slc22a19; no
human ortholog identified) [7, 9].
The basolateral uptake transporters Oat1 and Oat3
share a high degree of amino acid sequence identity
(mOat1 versus mOat3 = 48% and hOAT1 versus hOAT3
= 50%). This protein homology likely contributes to the
greatly overlapping substrate profiles exhibited by these two
transporters. However, despite this general similarity, the
individual aﬃnities for the same substrate often diﬀer greatly
between Oat1 and Oat3 [7]. Further, unique substrates that
interact with Oat1, but not with Oat3 (and vice-versa)
have been identified [7]. Preclinical in vivo studies utilizing
knockout mouse lines have also demonstrated that, in terms
of renal transport function, expression of Oat1 does not
fully compensate for loss of Oat3 (and vice-versa) [13–16].
For example, Oat1 knockout mice exhibited complete loss
of active tubular para-aminohippuric acid (PAH) secretion
and decreased renal clearance of the diuretic, furosemide,
which was accompanied by significantly decreased eﬃcacy
(monitored as decreased natriuresis and increased ED50)
[16]. Pharmacokinetic studies performed in Oat3 knockout
mice detected reduced clearance and increased plasma half-
life of benzylpenicillin, ciprofloxacin, and methotrexate [13–
15]. However, PAH clearance was unaﬀected in these animals
[14].
Tomore fully understand the therapeutic eﬃcacy (and/or
adverse eﬀects) of herbal products and optimize their clinical
use, a more thorough identification of the active components
they contain and greater knowledge of the mechanisms
determining their pharmacokinetic and pharmacodynamic
properties, for example, transporter interactions, need to be
elucidated. The aim of the present study was to characterize
the eﬀects of six active hydrophilic Danshen components
on the transport activity of mOat1 and mOat3. Danshen
components producing the greatest inhibition were exam-
ined further in studies designed to elucidate the mech-
anism of inhibition (competitive versus noncompetitive
versus uncompetitive). Combining this information with
dose response data, we derived inhibitory constants (Ki
values). Evidence was gathered showing that LSA, RMA,
and SAA serve as potent competitive inhibitors of mOat1
and mOat3 and indicating the potential for marked herb-
drug interactions, such as altered pharmacokinetics and
pharmacodynamics of coadministered clinical therapeutics
that are OAT substrates.
2. Materials and Methods
2.1. Purified Chemicals. The Danshen components LSA,
PCA, RMA, SAA, SAB, and TSL (≥96% purity) were
obtained from Tauto Biotech (Shanghai, China). Their
chemical structures are illustrated in Figure 1. Tritiated PAH
([3H]PAH) and estrone sulfate ([3H]ES) were purchased
from PerkinElmer Life and Analytical Sciences (Waltham,
MA) and unlabeled PAH, ES, and probenecid were pur-
chased from Sigma-Aldrich (St. Louis, MO, USA).
2.2. Tissue Culture. Derivation of the stably transfected
Chinese hamster ovary (CHO) cell lines expressing mOat1
(CHO-mOat1), mOat3 (CHO-mOat3), and the empty vec-
tor (FRT) transfected control cell line (CHO-FRT) was
described previously [13, 15]. Cell lines were maintained at
37◦C with 5% CO2 in DMEM F-12 media (Mediatech, Inc.,
Herndon, VA, USA) containing 10% serum, 1% Pen/Strep,
and 125 μg/mL hygromycin B.
2.3. Cell Accumulation Assays. Cell transport assay proce-
dures were adapted from those previously published [15, 17].
In brief, 2 × 105 cells/well were seeded in 24-well tissue cul-
ture plates and grown in the absence of antibiotics for 48 hr.
On the day of the experiment, cells were equilibrated with
transport buﬀer for 10min (500 μL of Hanks’ balanced salt
solution containing 10mM HEPES, pH 7.4). Equilibration
buﬀer was replaced with 500 μL of fresh transport buﬀer con-
taining 5 μM [3H]PAH or 1 μM [3H]ES (0.25 μCi/mL) with
or without inhibitors. After incubation, cells were immedi-
ately rinsed three times with ice-cold transport buﬀer, lysed,
and analyzed via liquid scintillation counting. Uptake values
were normalized to corresponding total protein content in
cell lysates as determined by the Bradford method. Substrate
accumulation is reported as picomoles of substrate per mil-
ligram protein. Substrate concentration and accumulation
time used for kinetic analysis of mOat3 (1 μM ES for 1min,
Km = 12.2 ± 4.8 μM) were determined previously [15].
Substrate concentration (Figure 3) and accumulation time
(data not shown) for mOat1 kinetic analysis (5 μM PAH for
2min, Km = 13.0± 3.3μM) were determined in this study.
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Figure 1: Chemical structures of six active hydrophilic Danshen components. MW: molecular weight.
Kinetic calculations were performed using GraphPad Prism
Software version 5.0 (GraphPad Software Inc., San Diego,
CA, USA). Michaelis constant (Km) values were calculated
by nonlinear regression using the Michaelis-Menten model.
Mode of inhibition was identified by using mixed model
inhibition analysis [18] as follows:
Vmax Apparent = Vmax(1 + [I]/(α× Ki)) ,
Km Apparent = Km 1 + [I]/Ki(1 + [I]/(α× Ki)) ,
Y = Vmax Apparent × x
Km Apparent + x
,
(1)
where Vmax, Ki, and I represent the maximum transport
velocity without inhibitor, the inhibition constant generated
from the data set under analysis, and the concentration
of inhibitor, respectively. In this study, three curves were
constructed (no inhibitor, plus two selected inhibitor con-
centrations) with uptake of substrate plotted as a function of
its concentration for each condition. These untransformed
data were fit to the equations shown above using nonlinear
regression to estimate the α values summarized in Table 1.
The parameter, α, can then be used to determine the mode
of inhibition. When α is very large (α > 1), it indicates
competitive inhibition. Otherwise, it indicates noncompet-
itive inhibition (α = 1) or uncompetitive inhibition (0 <
α < 1). To estimate Ki values, IC50 values were calculated
using nonlinear regression and inserted into the Cheng-
Prusoﬀ equation: Ki = IC50/(1 + [Substrate]/Km) [19].
Results were confirmed by repeating all experiments at least
three times with triplicate wells for each data point in every
experiment.
2.4. Statistics. Data are reported as mean ± S.D. or mean
± S.E.M. as indicated. Statistical diﬀerences were assessed
using one-way ANOVA followed by post hoc analysis
with Dunnett’s t-test or using Student’s unpaired t-test, as
indicated (α = 0.05).
3. Results
3.1. Inhibition of mOat1 and mOat3 by Hydrophilic Danshen
Components. Accumulation of PAH in the CHO-mOat1
cell line (98.5 ± 14.6 pmol/mg protein/10min) was ∼30
fold greater than that in the background control CHO-
FRT cells (3.3 ± 0.7 pmol/mg protein/10min; Figure 2(a)).
Initially, an uptake assay with excess (1mM) Danshen
components was performed to identify which, if any, of the
compounds might interact with mOat1 (Figure 2(a)). Each
of the Danshen components, LSA, PCA, RMA, SAA, SAB,
and TSL, significantly inhibited PAH uptake in CHO-mOat1
cells (P < 0.001) under these conditions. LSA, SAB, and
TSL produced approximately 70–85% inhibition, whereas
PCA, RMA, and SAA, each reduced PAH accumulation to
background level (>95% inhibition), similar to the proto-
typical OAT inhibitor, probenecid. Further, the addition of
these compounds (1mM) did not significantly influence the
low, probenecid-insensitive (i.e., nonspecific) PAH uptake
in the CHO-FRT cells (data not shown), indicating that
the reduction in uptake of PAH in the CHO-mOat1 cells
is attributable to the inhibition of mOat1 activity and that
CHO-FRT PAH level serves as an appropriate background
correction factor.
Stably transfected mOat3-expressing (CHO-mOat3)
cells showed significantly greater accumulation of ES
(∼20 fold) relative to control CHO-FRT cells (5.02 ±
0.19 versus 0.25 ± 0.04 pmol/mg protein/10min, resp.,
Figure 2(b)). Similar to mOat1, all of the Danshen compo-
nents (1mM) significantly inhibited mOAT3-mediated ES
uptake (P < 0.001). SAB and TSL produced approximately
53% and 55% inhibition, respectively. LSA, PCA, RMA,
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Figure 2: Inhibition profile of mOat1 and mOat3. (a) Inhibition of mOat1-mediated uptake of [3H]PAH (5 μM) by LSA, PCA, RMA, SAA,
SAB, TSL, and probenecid (1000 μM) was measured in the CHO-mOat1 cells (10min). Background PAH accumulation was measured in
CHO-FRT cells in the absence of inhibitor and is shown to provide a clear gauge of the low background in the experimental system. (b)
Inhibition of mOat3-mediated uptake of [3H]ES (1 μM) by LSA, PCA, RMA, SAA, SAB, TSL, and probenecid (1000 μM) was measured in
the CHO-mOat3 cells (10min). Background ES accumulation was measured in CHO-FRT cells in the absence of inhibitor and is shown to
provide a clear gauge of the low background in the experimental system. Values are mean ± S.D. of triplicate values. ∗∗∗denotes P < 0.001
as determined by one-way ANOVA followed by Dunnett’s t-test.
and SAA, like probenecid, blocked virtually all (>91%)
mOat3-mediated ES transport (Figure 2(b)). As with PAH,
these compounds (1mM) failed to consistently or signifi-
cantly influence nonspecific ES uptake in CHO-FRT cells
(data not shown), indicating that the reduction in uptake of
ES in the CHO-mOat3 cells is attributable to the inhibition
of mOat3 activity and that CHO-FRT ES level serves as an
appropriate background correction factor.
3.2. Determination of the Type of Inhibition Induced by
Danshen Components on mOat1 and mOat3. Although PCA
exhibited as potent inhibition as LSA, RMA, and SAA, it is
not a major component in Danshen preparations. Therefore,
the mechanism of inhibition of mOat1/mOat3-mediated
transport of PAH/ES was investigated for LSA, RMA, and
SAA (Table 1). Our previous work with CHO-mOat3 cells
showed that ES accumulation was linear through the first
5min and that ES exhibited a Km of 12.2 ± 4.8 μM [15].
In this study, time course evaluations in CHO-mOat1 cells
indicated that PAH accumulation was linear through at least
the first 5min, and Km was estimated as 13.0 ± 3.3μM
(Figure 3). Using these parameter estimates as guidelines,
Table 1: Estimated α values from mixed inhibition model analysis
for LSA, RMA, and SAA.
Compound mOat1 mOat3
LSA 6.7× 1011 1.9× 1015
RMA 1.3× 1012 2.5× 1019
SAA 2.6× 1014 3.4× 1014
Values are reported as mean. The S.E.M. is not applicable in this analysis.
kinetic experiment conditions were set to 1 μM ES for
1min and 5 μM PAH for 2min. The background corrected
untransformed data for LSA, RMA, and SAA on mOat1
or mOat3 was fit to the mixed inhibition model, which
incorporates competitive, noncompetitive, and uncompeti-
tive inhibition modes. The estimated α values were found to
be much larger than 1, indicating that inhibition of mOat1-
and mOat3-mediated transport by LSA, RMA, and SAA was
competitive in nature (Table 1).
3.3. Inhibition Potencies of LSA, RMA, and SAA. To allow
direct comparison of inhibition potencies of LSA, RMA, and
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Figure 3: Michaelis-Menten kinetics of PAH transport in CHO-
mOat1 cells. In order to calculate Ki values for mOat1, the Km value
for PAH needed to be determined in the CHO-mOat1 cell system.
Uptake of [3H]PAH was measured for 2min at room temperature
in CHO-mOat1 (closed triangles) and CHO-FRT (open squares)
cells in order to construct a saturation curve. The corrected
curve (closed circles) was obtained by subtracting the nonspecific
background uptake as measured in the CHO-FRT cells from CHO-
mOat1 accumulation to allow analysis of mOat1-mediated activity.
Experiments were repeated three times in triplicate, and Michaelis
constant (Km) values were calculated by nonlinear regression using
the Michaelis-Menten model. The Km for PAH on mOat1 was
estimated as 13.0± 3.3μM (mean ± S.E.M.). Graph shown is from
a representative experiment with values plotted as mean ± S.D.
(n = 3).
SAA for mOat1 and mOat3, experiments were conducted to
determine the inhibition constant (Ki) values (Figures 4 and
5 and Table 2). Since LSA, RMA, and SAA were found to
be competitive inhibitors of mOat1- and mOat3-mediated
transport, subsequent Ki analysis was performed using com-
petitive inhibition. Applying increasing concentrations of
unlabeled test compounds (10−7 to 5 × 10−4M), inhibition
of mOat1- or mOat3-mediated transport was measured
(Figures 4 and 5). Inhibition constants were estimated as
14.9 ± 4.9μM for LSA, 5.5 ± 2.2μM for RMA, and 4.9 ±
2.2μM for SAA on mOat1-mediated transport (Table 2).
Values determined in the CHO-mOat3 cell line were 31.1 ±
7.0μM for LSA, 4.3 ± 0.2μM for RMA, and 21.3 ± 7.7μM
for SAA (Table 2). For all of these analyses the coeﬃcient
of determination (r2) was >0.9. No significant diﬀerences
between Ki values for mOat1 and mOat3 were detected as
determined by Student’s unpaired t-test.
4. Discussion
Many natural products, which are extracted from living
organisms, have beneficial biological or pharmacological
activities and have been used as medicines throughout
the world for more than 1,000 years. Today, they are
often used as first-line therapeutics, dietary supplements, or
complementary/alternative medicines, and it is reported that
∼20% of adults in the United States are taking an herbal
product [20]. Over the last decade a number of studies
have identified transporter proteins, including OATs, as
sites of drug-drug and natural product-drug interactions.
For example, the dietary polyphenol, ellagic acid, which
exhibits beneficial antioxidant and anticancer properties, was
demonstrated to be one of the most potent inhibitors of
hOAT1 (IC50 = 207 nM) identified to date [21]. Recently,
the nephrotoxin aristolochic acid, which is produced by
Aristolochia sp. plants, was identified as the causative agent
for “Chinese herbs nephropathy” (now referred to as aris-
tolochic acid nephropathy). When investigated, aristolochic
acid was found to be a high-aﬃnity substrate for bothmOat1
(Km = 790 nM) and mOat3 (Km = 514 nM), suggesting that
these transporters are key mediators in the renal proximal
tubule cell accumulation of this toxicant [10, 22]. Thus,
this interaction likely explains the biochemical mechanism
underlying the acutely targeted, proximal tubule specific
nature of aristolochic acid toxicity. Clearly, OATs expressed
in the renal proximal tubule represent highly probable sites
of natural product-drug (or natural product-endogenous
substrate) interactions. Further studies such as these are
needed in order to establish informed safety and eﬃcacy
profiles for herbal products.
Danshen, a traditional herbal medicine, continues to
be used in the treatment of angina, myocardial ischemia,
and other cardiovascular diseases throughout the world
including Asia, Europe, and North America [1]. In 2010,
the Danshen pharmaceutical product, Fufang Danshen
Dripping Pill, successfully completed Phase II clinical tri-
als in the United States (http://clinicaltrial.gov/ct2/show/
NCT00797953?term=tasly&rank=1). To date, however, no
formal studies examining the interaction between OATs
and hydrophilic Danshen compounds, which are small
organic acids and known to be major components in its
pharmaceutical products, have been reported. Therefore, in
the present study, we investigated whether any of the six
purported active Danshen components, LSA, PCA, RMA,
SAA, SAB, and TSL, interacted with the transporters mOat1
and/or mOat3 (Figures 1 and 2).
A major advantage of this study is that while Danshen
preparations (and indeed the majority of herbal medicines)
include multiple active components, purified preparations
of individual Danshen extract components were used. Thus,
the strength of interaction of each compound could be
quantified independently versus the merged eﬀects of a
mixture containing all of the compounds. Similarly, since
the transporters were expressed in isolation, the interac-
tion of each individual compound with each individual
transporter could be specifically assessed versus the in vivo
situation where multiple transporter proteins are expressed
simultaneously in a tissue, and the measured response
is possibly an amalgamation of the activities of multiple
transporter proteins. While under certain conditions all
six compounds significantly inhibited mOat1- and mOat3-
mediated transport, LSA, RMA, and SAA emerged as potent
competitive inhibitors (Figures 4 and 5 and Tables 1 and
2). The rank order of their potencies was diﬀerent between
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Figure 4: Ki determination for LSA, RMA, and SAA in the CHO-mOat1 cell line. Two minute uptake of [3H]PAH (5 μM) in CHO-mOat1
cells was measured in the presence of increasing concentrations (10−7 to 5 × 10−4M) of LSA, RMA, and SAA. Data were corrected for
nonspecific background measured in the CHO-FRT cells prior to kinetic analysis. Ki values were determined with non-linear regression and
the “one-site competition” model using GraphPad Prism software. Experiments were repeated three times in triplicate with the mean Ki±
S.E.M. reported in Table 2. Graphs shown are from representative experiments with values plotted as mean ± S.D. (n = 3).
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Figure 5: Ki determination for LSA, RMA, and SAA in the CHO-mOat3 cell line. One minute uptake of [3H]ES (1 μM) in CHO-mOat3 cells
was measured in the presence of increasing concentrations (10−7 to 4× 10−4M) of LSA, RMA, and SAA. Data were corrected for nonspecific
backgroundmeasured in the CHO-FRT cells prior to kinetic analysis.Ki values were determined with non-linear regression and the “one-site
competition” model using GraphPad Prism software. Experiments were repeated three times in triplicate with the mean Ki± S.E.M. reported
in Table 2. Graphs shown are from representative experiments with values plotted as mean ± S.D. (n = 3).
the two transporters with RMA ≈ SAA > LSA for mOat1
and RMA > SAA ≈ LSA for mOat3. While statistically not
diﬀerent, the Ki ratio (Table 2) suggests that mOat1 may
have a slightly higher aﬃnity (lower Ki) for LSA and SAA
than mOat3. However, in general, all of the values are quite
similar and exhibit well below an order of magnitude in
diﬀerence. The estimates are comparable to those reported
for the strong OAT inhibitor, probenecid, Ki = 6.4 and
4.6 μM for mOat1 and mOat3, respectively [7, 23, 24].
Thus, LSA, RMA, and SAA may aﬀect the disposition and
elimination of coadministered drugs that are also mOat1
and mOat3 substrates. This may be particularly relevant
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Table 2: Estimated Ki (μM) values for mOat1- and mOat3-
mediated transport.
Compound mOat1 mOat3 Ki ratio (mOat1/mOat3)
LSA 14.9± 4.9 31.1± 7.0 0.48
RMA 5.5± 2.2 4.3± 0.2 1.29
SAA 4.9± 2.2 21.3± 7.7 0.23
Values are reported as mean ± S.E.M. (n = 3). No significant diﬀerences
between Ki values for mOat1 and mOat3 were detected (P < 0.05) as
determined by Student’s unpaired t-test.
in patients suﬀering from coronary disease where Danshen
pharmaceutical products could be combined with drugs such
as angiotensin converting enzyme inhibitors, and studies
with the human orthologs of these transporters need to be
conducted.
In vivo pharmacokinetic studies have indicated that
elimination of hydrophilic Danshen components involves
active renal secretory pathways. In rats, the unbound renal
clearance of TSL was ∼5X greater than the glomerular
filtration rate [25]. A separate study in rats found that
spiking additional SAA into Danshen preparations increased
the AUC of SAB (82.4%) and TSL (26.7%) and markedly
reduced their clearances (46.8% and 32.9% for SAB and
TSL, resp.) [26]. As we determined that SAA was a potent
competitive mOat1/mOat3 inhibitor, and SAB and TSL can
interact with mOat1 and mOat3, our data suggest that these
in vivo results may be explained by competition for transport
on Oat1/Oat3. An in vivo pilot study conducted in healthy
humans reported Cmax values for LSA and RMA of 2.1 μM
and 6.7 μM after i.v. dosing of a Danshen product [5]. These
Cmax values are ∼0.07–1.56-fold higher than the Ki values
for mOat1 and mOat3 determined in the present study
(Table 2). As recommended by the FDA Guidance for Drug
Interaction Studies, when unbound Cmax/IC50 (or Ki) ≥ 0.1,
it indicates that drug-drug interactions may occur in vivo
[27]. Unfortunately, the plasma protein binding for LSA and
RMA has not been reported, while TSL showed 25% plasma
protein binding in rat plasma [25]. However, if we assume
RMA to be highly protein bound (90%), the unbound
Cmax/Ki ratio for RMA would be 0.12 and 0.16 on mOat1
and mOat3, respectively, indicating potential for herb-
drug interactions. Naturally, if human OAT orthologs show
similar (or higher) aﬃnities, possible herb-drug interactions
should be considered.
A recent investigation indicated that flavonoid and
hydroxycinnamic acid aglycones and their phase II metabo-
lites (e.g., sulfate and glucuronide conjugates) significantly
inhibit hOAT1 and hOAT3 transport activity [28, 29]. It is
known that after oral administration in healthy volunteers,
the majority of RMA exists as such conjugated forms, as well
[30, 31]. Currently, there are no reports on characterization
of LSA and SAA metabolites in human plasma, while SAA
might undergomethylation and glucuronidation in rats [32].
Therefore, studies elucidating the metabolic pathways of
these compounds are needed such that potential interac-
tions of their metabolites with Oat1 and/or Oat3 can be
examined.
In addition, there are other transporter families known
to interact with small organic anions, for example, the
multidrug resistance-associated proteins (MRPs, ABCC
family) and the organic anion transporting polypeptides
(OATPs, SLCO family). For the most part these latter
two transporter families and the OATs have fairly distinct
substrate interactions; however, the possibility that they also
may contribute to the overall clinical pharmacokinetic profile
of Danshen components in vivo needs to be considered until
investigated directly. For example, it was recently suggested
that SAB might be an OATP substrate based upon inhibition
of total and biliary clearance of SAB by rifampicin, an OATP
inhibitor, in rats [33].
Finally, the amount of each active component in Danshen
preparations varies with diﬀerent cultivation regions and
manufacturing processes [4]. The variation of RMA in raw
plant material was observed to be∼16-fold between diﬀerent
growing regions, and the dose of RMA ranged from 4.1 to
160mg (∼40 fold) in injectable dosage forms produced by
diﬀerent manufacturers [4, 5]. In a clinical study, the Cmax
of RMA after i.v. infusion of a 160mg dose was 1.2–1.6-fold
higher than the Ki values for mOat1 and mOat3 [5]. These
data suggest that, clinically, patients either would or would
not have the potential for significant herb-drug interactions
solely depending upon which manufacturer’s product they
were administered. Thus, although tanshinone II A, SAB, and
protocatechuic aldehyde have been used as quality control
markers in the manufacture of Danshen pharmaceutical
dosage forms, the work presented here indicates that perhaps
the content of LSA, RMA, and SAA should be monitored and
controlled as well.
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